Commentary: Modifying acute otitis media: Implications of immunization with pneumococcal conjugate vaccine

Pediatric Infectious Disease Journal

Volumn 23, Issue 9, 2004, Pages 839-841

  Pelton, Stephen I ^a  

^a BOSTON MEDICAL CENTER   (United States)

Author keywords

7 valent pneumococcal conjugate vaccine; Acute otitis media; Immunizations

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CEFDINIR; CEFIXIME; CEFPODOXIME; CEFPROZIL; CEFUROXIME; PNEUMOCOCCUS VACCINE; ANTIINFECTIVE AGENT; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; MENINGOCOCCUS VACCINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; HUMAN; IMMUNIZATION; NOTE; OTITIS MEDIA; OUTCOMES RESEARCH; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TREATMENT FAILURE; VACCINATION; ACUTE DISEASE; AGE DISTRIBUTION; CHILD; FEMALE; IMMUNOLOGY; INCIDENCE; INFANT; MALE; MICROBIOLOGY; PRESCHOOL CHILD; PROGNOSIS; RISK ASSESSMENT; SEX RATIO; STREPTOCOCCUS INFECTION;

ACUTE DISEASE; AGE DISTRIBUTION; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INCIDENCE; INFANT; MALE; MENINGOCOCCAL VACCINES; OTITIS MEDIA; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; PROGNOSIS; RISK ASSESSMENT; SEX DISTRIBUTION; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 13544257413     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000138453.32886.a6     Document Type: Note

References (15)

1. Block SL, Hedrick J, Harrison CJ, et al. Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media. Pediatr Infect Dis J. 2004;23:829-833.
2. Carsey JR, Pichichero ME. Changes in frequency and pathogens causing acute otitis media in 1995-2003. Pediatr Infect Dis J. 2004;23:824-828.
3. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
4. Shurin PA, Pelton SI, Scheifele D, Klein JO. Otitis media caused by non-typable, ampicillin-resistant strains of Haemophilus influenzae. J Pediatr. 1976;88:646-649.
5. Dagan R, Leibovitz E, Cheletz G, Leiberman A, Porat N. Antibiotic treatment in acute otitis media promotes superinfection with resistant Streptococcus pneumoniae carried before initiation of treatment. J Infect Dis. 2001;183:880-886.
6. Ghaffar F, Muniz LS, Katz K, et al. Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. Clin Infect Dis. 2000;31:875-880.
7. Ghaffar F, Muniz LS, Katz K, et al. Effect of large dosages of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae, Haemophilus influenzae, nonpneumococcal α-hemolytic streptococci and Staphylococcus aureus in children with acute otitis media. Clin Infect Dis. 2002;34:1301-1309.
8. Dabernat H, Geslin P, Megraud F, et al. Effects of cefixime or coamoxiclav treatment on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media. J Antimicrob Chemother. 1998;41:235-238.
9. Block SL, Busman TA, Paris M, Bukofzer S. Comparison of 5 day cefdinir treatment with 10-day low dose amoxicillin/clavulanate (45 mg/kg/day) treatment for acute otitis media. Pediatr Infect Dis J 2004;23:834-838.
10. Leibovitz E, Dagan R, Arguedas A, et al. An evaluation of once daily cefdinir 25 mg/kg oral suspension (CEF) in children with acute otitis media (AOM) at risk of persistent or recurrent otitis media (PROM). Paper presented at: 22nd Annual Meeting of the European Society for Paediatric Infectious Diseases; May 2004; Tampere, Finland.
11. Dagan R, Hoberman A, Johnson C, et al. Bacteriologic and clinical efficacy of high dose amoxicillin/clavulanate in children with acute otitis media. Pediatr Infect Dis J. 2001;20:829-837.
12. Lowdin E, Cars O, Odenholt I. Pharmacodynamics of amoxicillin/clavulanate acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clin Microbiol Infect. 2002;8:646-653.
13. Kudo N. Pediatric patients with refractory acute otitis media due to BLNAR. Jpn J Antibiot. 2001;54(suppl B):102.
14. Leibovitz E, Piglansky L, Raiz S, et al. Bacteriologic and clinical efficacy of oral gatifloxacin for the treatment of recurrent/nonresponsive acute otitis media: an open label, noncomparative, double tympanocentesis study. Pediatr Infect Dis J. 2003;22:943-949.
15. Wigger C, MacKenzie G, Tipakalippa P, et al. Impact of the 7-valent pneumococcal conjugate vaccine on the clinical course of otitis media in 3 Australian Aboriginal communities. Abstracts from the 4th International Symposium on Pneumococci and Pneumococcal Disease. 2004; Helsinki, Finland; 204.